Orexo
Develops pharmaceuticals and digital therapies for substance use and mental health.
ORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000736415 (+2 more)
- LEI:
- 549300LJ5CCWDPTK9Z08
- Country:
- Sweden
- Address:
- Box 303, 751 05 UPPSALA
- Website:
- https://orexo.com/
- Sector:
- Manufacturing
Description
Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2016-10-20 12:15 | English | 1.4 MB | |||
| 2016-10-20 08:00 |
Delårsrapport Januari-September 2016
|
Swedish | 1.4 MB | ||
| 2016-10-20 08:00 |
Interim Report January-September 2016
|
English | 1.4 MB | ||
| 2016-10-06 08:00 |
FDA godkänner unikt låg dos av Zubsolv®
|
Swedish | 325.1 KB | ||
| 2016-10-06 08:00 |
FDA Approves Unique Low Dosage of Zubsolv®
|
English | 326.3 KB | ||
| 2016-10-04 08:00 |
Mundipharma och Orexo meddelar att en EU regulatorisk ansökan lämnats in för Zu…
|
Swedish | 427.4 KB | ||
| 2016-10-04 08:00 |
Mundipharma and Orexo announce EU regulatory submission for Zubsolv®
|
English | 378.1 KB | ||
| 2016-09-02 08:00 |
Orexo slutför REZOLV studien, omfattande 1080 patienter, och rapporterar om för…
|
Swedish | 347.2 KB | ||
| 2016-09-02 08:00 |
Orexo completes 1,080 patient REZOLV study and reports on improved treatment of…
|
English | 476.1 KB | ||
| 2016-07-12 12:00 | Swedish | 1.4 MB | |||
| 2016-07-12 12:00 | English | 1.4 MB | |||
| 2016-07-12 08:00 |
Interim Report January-June 2016
|
English | 1.4 MB | ||
| 2016-07-12 08:00 |
Delårsrapport januari-juni 2016
|
Swedish | 1.4 MB | ||
| 2016-07-07 08:00 |
Orexo välkomnar besked om ökad tillgång till behandling av opiatberoende i USA
|
Swedish | 324.4 KB | ||
| 2016-07-07 08:00 |
Orexo welcomes increased access to treatment for patients with opioid dependenc…
|
English | 324.5 KB |
Automate Your Workflow. Get a real-time feed of all Orexo filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Orexo
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Orexo via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-11 | Nikolaj Arrild Sørensen | Other | Buy | 2,460 | 35,178.00 SEK |
| 2025-04-04 | Nikolaj Arrild Sørensen | Other | Buy | 3,500 | 47,530.00 SEK |
| 2024-03-26 | Fredrik Järrsten | Other | Buy | 3,000 | 44,040.00 SEK |
| 2023-11-24 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 44,640.00 SEK |
| 2023-11-08 | Fredrik Järrsten | Other | Buy | 1,500 | 23,715.00 SEK |
| 2023-02-24 | Nikolaj Arrild Sørensen | Other | Buy | 11,500 | 188,945.00 SEK |
| 2023-01-27 | Fredrik Järrsten | Other | Buy | 4,500 | 79,695.00 SEK |
| 2022-07-26 | Michael Matly | Other | Buy | 2,820 | 60,777.77 SEK |
| 2022-07-21 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 61,500.00 SEK |
| 2022-07-15 | James Noble | Other | Buy | 18,500 | 394,252.80 SEK |
Peer Companies
